• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

    Tevogen Bio Expands AI Collaboration With Microsoft On Azure

    GLOBENEWSWIRE

    Tevogen Bio Highlights AI-Driven Drug Development At JPM Conference

    GLOBENEWSWIRE

    Tevogen Bio Hosts Panels on AI, Health Economics at JP Morgan

    GLOBENEWSWIRE

    Tevogen Bio to Host AI in Biopharma Panel at JP Morgan

    GLOBENEWSWIRE

    Tevogen Bio Strengthens IP with AI Patent to T Cell Therapies

    GLOBENEWSWIRE

    Tevogen Bio Host Panel on Economics at 43rd J.P. Morgan Conference

    GLOBENEWSWIRE

    Tevogen Bio to Attend 43rd J.P. Morgan Healthcare Conference

    GLOBENEWSWIRE

    Dr. Ryan Saadi Commends Public Service & Congratulates Mayor

    GLOBENEWSWIRE

    Tevogen Bio Prepares for Growth Strategy Support

    GLOBENEWSWIRE

    Tevogen Bio CEO Reflects on Public Support, Prioritizes Value

    GLOBENEWSWIRE

    Tevogen Bio Reports Q3 2024 Results, Improves Financial Position

    GLOBENEWSWIRE

    Tevogen Founder Reflects on Preserving Shareholder Value

    GLOBENEWSWIRE

    Tevogen Founder Reflects on Shareholder Value Amid Growth

    GLOBENEWSWIRE

    Tevogen Bio Nears R&D, Manufacturing Deal & $36M Credit

    GLOBENEWSWIRE

    Tevogen Bio Partners with Microsoft for HPV Target Identification

    GLOBENEWSWIRE

    Tevogen Bio CEO Ryan Saadi Recognized for Business Model

    GLOBENEWSWIRE

    Tevogen Bio Appoints Anthony Tarantino as Patient Advocate

    GLOBENEWSWIRE

    Tevogen Bio Partners with Microsoft to Accelerate Drug Development

    GLOBENEWSWIRE

    Tevogen Signs LOI with CD8 for $50M R&D Facility; No Equity Impact

    GLOBENEWSWIRE

    Tevogen Bio Reports Nasdaq Compliance, CEO Commits to Info Bridge

    GLOBENEWSWIRE

    Tevogen Bio Provides T Cell Therapy Guidance for Oncology

    GLOBENEWSWIRE

    Tevogen AI Partners with Microsoft for Drug Development

    GLOBENEWSWIRE

    Tevogen Bio To Provide Revenue Forecast Timelines This Week

    GLOBENEWSWIRE

    Tevogen Provides Clarity On CSO Share Sales For Tax Obligations

    GLOBENEWSWIRE

    Tevogen Reports Revenue Forecast Of Nearly $1 Billion In Launch Year

    GLOBENEWSWIRE

    Tevogen CEO Thanks Public For Support Of Patient Model.

    GLOBENEWSWIRE

    Tevogen Investors Celebrate Recognition Of Biopharma Model

    GLOBENEWSWIRE

    Tevogen Bio Forecasts $1B Revenue In Launch Year, $10-14B Over 5

    GLOBENEWSWIRE

    Tevogen Bio Thanks Warren Township For Honoring CEO Dr. Ryan Saadi

    GLOBENEWSWIRE

    Tevogen Bio Highlights the Publication of Promising Trial Data

    GLOBENEWSWIRE

    Tevogen Bio Leads in Developing Cell Therapies For HPV In Women

    GLOBENEWSWIRE

    Tevogen CEO Reaffirms Commitment To Closing Information Gap

    GLOBENEWSWIRE

    Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID

    GLOBENEWSWIRE

    Tevogen To Share $1B+ Revenue Potential Of Pipeline On 14th Oct 2024

    GLOBENEWSWIRE

    Tevogen Bio Highlights Trial Data And CEO Leads Patient Advocacy

    GLOBENEWSWIRE

    Tevogen Bio Meets Congress, Highlights Biotech Innovation

    GLOBENEWSWIRE

    Tevogen Bio Secures $6 Million Series C Preferred Stock Investment

    GLOBENEWSWIRE

    Tevogen Bio Eliminates Going Concern Doubts, Series B Preferred Shares

    GLOBENEWSWIRE

    Tevogen Bio Q2 2024 Results, Eliminates Going Concern Doubts, Series B Shares

    GLOBENEWSWIRE

    Tevogen Bio’s Advisory Chair, Professor Sten Vermund, Named USF Dean

    GLOBENEWSWIRE

    Tevogen Bio CEO Reaffirms Growth Strategy, Clarifies S-1 Filing

    GLOBENEWSWIRE

    Tevogen Bio Highlights Achievements And Considers Share Buyback

    GLOBENEWSWIRE

    Tevogen Bio Discusses Unmodified T Cell Tech With Nasdaq`s Ayanian

    GLOBENEWSWIRE

    Ryan Saadi Congratulates Marc Benioff On Yale Award

    GLOBENEWSWIRE

    Tevogen Files Registration Statement for Securities; No New Dilutive Issuances

    GLOBENEWSWIRE

    Tevogen Announces Phase I Clinical Trial Results for TVGN 489 in Blood Advances

    GLOBENEWSWIRE

    Tevogen.AI Head Discusses Bold Strategy to Shape the Future of T Cell Therapies

    GLOBENEWSWIRE

    Tevogen Bio Set to Join Russell 3000® Index

    GLOBENEWSWIRE

    Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing

    GLOBENEWSWIRE

    Correction: Tevogen Grateful For Inaugural Listing Event Attendance

    GLOBENEWSWIRE

    Tevogen Bio Expresses Gratitude For Attending Its Inaugural Post-Listing Event

    GLOBENEWSWIRE

    Tevogen Confirms Ongoing TVGN 489 Efficacy Against Dominant SARS-CoV-2 Strains

    GLOBENEWSWIRE

    Tevogen Bio Reports First Quarter 2024 Financial Results

    GLOBENEWSWIRE

    Tevogen Appoints William Keane VP Strategic Initiatives

    GLOBENEWSWIRE

    Tevogen Bio Up To $50M Financing For Operational Objectives

    GLOBENEWSWIRE

    Tevogen Bio FY 2023 Results, Upcoming Operational Objectives

    GLOBENEWSWIRE

    Tevogen CEO on Liability Elimination, AI Initiative, Appointments

    GLOBENEWSWIRE

    Tevogen CSO On Harnessing CTLs To Target Cancers

    GLOBENEWSWIRE

    Tevogen Appoints Tapan V Shah as Head of Investor Relations

    GLOBENEWSWIRE

    Tevogen Reports Series A-1 Preferred Stock Investment at $10 Conversion Price

    GLOBENEWSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.